about
Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasisAntileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major AmastigotesPharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study.Toxicokinetic and toxicodynamic (TK/TD) evaluation to determine and predict the neurotoxicity of artemisinins.Formulation and particle size reduction improve bioavailability of poorly water-soluble compounds with antimalarial activity.Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii.Field evaluation of diagnostic performance of malaria rapid diagnostic tests in western Kenya.Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infectionsModulating Acinetobacter baumannii biofilm development with molecules containing 3,4,5-trimethoxy-N,N',N'-trimethylbenzohydrazide moiety.Detection of influenza virus from throat and pharyngeal swabs with a nested duplex light cycler RT-PCR.
P50
Q28542936-55AB2B78-6648-4DA2-9F73-2EBEAB006E52Q30488470-2D63E281-AE1F-4A3A-8EDB-AEAB5AE90C65Q33958541-0B9543BD-EC85-4C1F-A827-C002FFFA4296Q34139685-EFF838A9-A06D-4CA9-A6F6-6F76EBD7D066Q36882689-1E468378-2CDE-452F-8259-5231B794FCD8Q36907360-9296A534-763B-46E3-9B85-844A189F298CQ37128281-EFDFFAA8-B9C5-4796-8BEE-575D14F622C3Q37240312-A981F48F-4FF1-4EAF-B372-DA3B33B74141Q37485056-CF30F251-641E-4FF7-9763-3EE03503C9EDQ37707806-15C85B55-E092-401A-ABA0-BCFFD3B55542Q38886170-804C45E6-C54B-42DF-BF6C-D19D473C20EFQ45723652-F83AC785-A156-4432-9572-82C93D8749FC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mark Hickman
@ast
Mark Hickman
@en
Mark Hickman
@es
Mark Hickman
@nl
Mark Hickman
@sl
type
label
Mark Hickman
@ast
Mark Hickman
@en
Mark Hickman
@es
Mark Hickman
@nl
Mark Hickman
@sl
prefLabel
Mark Hickman
@ast
Mark Hickman
@en
Mark Hickman
@es
Mark Hickman
@nl
Mark Hickman
@sl
P106
P21
P31
P496
0000-0001-8183-2076